Further opportunities may also be gained from targeting mechanisms of niche engagement or dormancy‐related molecules including AXL or TGFβ2 signaling (as discussed above) to reactivate dormant tumor cells for eradication using currently available chemotherapeutics.19 The gene discussed is TGFB2; the disease is neoplasm.